- AAA Prescription Discounts
Information on how AAA members can save money prescriptions at participating pharmacies.
- AANP State Practice Environment
Nurse practice laws and regulations for each state on an interactive map
- AATOD Guidelines for Using Naltrexone (Vivitrol) in OTPs
Describes alternative treatment for opioid dependence, Vivitrol (long acting naltrexone).
- A Closer Look at State Prescription Monitoring Programs (DEA FAQ's)
These FAQs address common questions regarding prescription drug monitoring programs.
- Adherence, Diversion and Misuse of Sublingual Buprenorphine
This 2010 (update 2014) Physician Clinical Support System (PCSS) document written by Dr. Judith Martin discusses types of aberrant behavior associated with buprenorphine and steps that can be taken to reduce the risk of abuse and diversion.
- Advancing access to addiction medications
Describes report by ASAM from 2013 on making addiction medications more accessible
- Applying the Substance Abuse Confidentiality Regulations 42 CFR Part 2
This document contains frequently asked questions and answers in reference to applying substance abuse confidentiality regulations
- Appropriate Use Checklist
Reminder of the safe use conditions and monitoring requirements for prescribing buprenorphine-containing transmucosal products for opioid dependence.
- ASAM Patient Placement Criteria
The ASAM Patient Placement Criteria for the Treatment of Substance-Related Disorders, Second Edition-Revised (Mee-Lee et al. 2001) lists the 5 basic levels of care available for adult substance users. These levels of care range from Early Intervention (for at-risk individuals) to Medically Managed Intensive Inpatient Treatment (for patients with severe disorders who require around-the-clock care). The Patient Placement Criteria classifies opioid maintenance therapy as a Level I treatment since it is most often conducted in outpatient settings.
- ASAM Summary of the Comprehensive Addiction and Recovery Act
Summarizes key features of CARA 2016.
- Assessment and Screening Instruments
This document provides a comprehensive collection of screening instruments and withdrawal assessments.
- AUDIT Questionnaire
The Alcohol Use Disorders Identification Test, or AUDIT, is comprised by ten questions that ask about the frequency and amount of alcohol consumption, the ramifications of the patient's drinking, and the concern of others for the patient's behavior.Patients are to be presented the form so that they can circle answers for each question. The AUDIT takes about 3 minutes to administer and score.
- Barriers to obtaining waivers to prescribe buprenorphine among HIV physicians
This survey of 375 physicians found that confidence addressing drug problems was positively associated with having a buprenorphine waiver.
- Behavioral Health Treatment Services Locator
The behavioral health treatment services locator is an on-line source of information for persons seeking treatment facilities in the United States or U.S. Territories for substance abuse/addiction and/or mental health problems.
- Buprenorphine-containing transmucosal products for opioid dependence (BTOD) REMS
REMS for buprenorphine published 2/2013 and revised 9/2013
- Buprenorphine: An Alternative to Methadone
This overview of buprenorphine includes a brief summary of the mechanism of action, regulatory requirements, pharmacology, and clinical studies.
- Buprenorphine: Considerations for Pain Management
This article reviews the role of buprenorphine in treating patients with pain.
- Buprenorphine and Buprenorphine plus Naloxone (en Español)
La buprenorfina sublingual, y la buprenorfina y naloxona. This patient education resource addresses common questions about buprenorphine treatment for opioid dependence.
- Buprenorphine and Primary HIV Care
This report describes points of intersection between HIV and primary care treatment, and discusses how to integrate HIV care into primary medicine.
- Buprenorphine Management - SAMHSA
Find information for providers on the waiver application and management process to prescribe or dispense buprenorphine for opioid dependency treatment.
- Buprenorphine Product Formulations Comparison
Compares the different formulations of buprenorphine products made by different drug companies.
- Buprenorphine Treatment: Training for Multidisciplinary Addiction Professionals
This is a training package developed by the Buprenorphine Awareness Blending Team to create awareness about buprenorphine among non-physician addiction professionals.
- Buprenorphine Waiver Notification Form. 30 Patient Notification
Slides describe the process of applying to prescribe buprenorphine for 30 patients by submitting a Waiver Notification form to SAMHSA.
- Buprenorphine Waiver Notification Form. 275 Patient Notification
Slides describe the process of applying to prescribe buprenorphine for 275 patients by submitting a Waiver Notification form to SAMHSA.
Screening test for alcohol and drugs.
- CDC Guideline for Prescribing Opioids for Chronic Pain
Clinical guidelines, literature review, and analysis of the evidence on the use of opioids for chronic pain. Recommendations are also made for prescribing opioids for acute pain.
- Clinical Laboratory Improvement Amendments (CLIA) - Currently Waived Analytes
The following is a list of currently waived analytes that are used in laboratory test systems. The list provides the analyte name as well as a link to the waived test system.
- Clinical Opioid Withdrawal Scale (COWS)
This PDF Document contains the Clinical Opioid Withdrawal Scale (COWS), a common instrument used to assess a patient's opioid withdrawal severity.
- Clinical Pathway for Buprenorphine
This flow chart for buprenorphine treatment displays the steps to patient recovery, from initial patient contact or referral, through intake process, induction, day #2, stabilization, maintenance, and tapering.
- Common Side Effects of Buprenorphine
- Comprehensive Addiction and Recovery Act of 2016
The House of Representatives Filing Copy
- Consent Form for Buprenorphine Treatment During Pregnancy
This consent form -- reproduced with permission from the Boston Medical Center -- can be used with your pregnant patients who want to continue taking buprenorphine during pregnancy.
- Consent to Release of Information Under Title 42, Part 2, Code of Federal Regulations
An example of the wording and structure necessary in a consent for release of information form.
- CRAFFT: Brief Screening Tool for Adolescents
THE CRAFFT is a screening instrument used to detect alcohol and other drug abuse.
The Drug Abuse Screening Test, or DAST, is a self-administered test designed to provide a brief screening for drug abuse, followed by further assessment by a health care professional if necessary.
- DATA 2000
This page provides links to the full text, summary, and physician waiver requirements under DATA 2000.
- Detecting Substance Abuse and Dependence: Red Flags, and Risk Factors
Lists the psychosocial and physical indications of substance abuse in general as well as the specific physical symptoms of opioid use (Source: Clinical Tools, Inc., 2004).
- Diagnosis and Treatment of Drug Abuse in Family Practice
This article provides guidance on the treatment of alcohol and drug abuse, and discusses various treatment plans.
- Diagnostic and Statistical Manual of Mental Disorders (DSM 5)
Manual for diagnosing mental health problems with diagnostic criteria and diagnostic codes.
- Drug-Drug Interactions in Opioid Therapy App
This website offers a tool that provides access to information on the likelihood of drug−drug interactions between either methadone or buprenorphine and 120 commonly prescribed drugs.
- Drug Abuse Screening Test (DAST)
Concerned about your use — or abuse — of drugs? With 20 questions, this simple self-test may help you identify aspects of your drug use which could be problematic. This test specifically does not include alcohol use.
- Drug Interactions: Cytochrome P450 Drug Interaction Table
This table is designed as a hypothesis testing, teaching and reference tool for physicians and researchers interested in drug interactions that are the result of competition for, or effects on the human cytochrome P450 system.
Clinicians and health care providers may find an abbreviated clinical table designed for practical use during prescribing more useful.
The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. A drug appears in a column if there is published evidence that it is metabolized, at least in part, via that isoform. It does not necessarily follow that the isoform is the principal metabolic pathway in vivo, or that alterations in the rate of the metabolic reaction catalyzed by that isoform will have large effects on the pharmacokinetics of the drug.
- Drug Interactions Between Methadone or Buprenorphine and other Medications
Table of drug Interactions between methadone or buprenorphine and other medications from a review by McCance-Katz, Sullivan, and Nallani (2010).
- Drug Interactions Checker
This website provides a "Drug Interactions Checker" that explains drug interactions. Furthermore, the significance level of the drug interaction is classified as major, moderate, or minor drug interactions. You can also check for food/lifestyle and disease interactions.
- DSM-5 Criteria for Opioid Use Disorder
The following are the DSM-5 diagnostic criteria for Opioid Use Disorder
- DSM 5 Criteria for Opioid Intoxication
The following is the DSM 5 diagnostic criteria for
- DSM 5 Criteria for Opioid Withdrawal
Lists the DSM 5 Criteria for Opioid Withdrawal (APA, 2013).
- DSM 5 Criteria for Opioid Withdrawal
Lists the clinical criteria for opioid withdrawal.
- DSM 5 Diagnostic Codes Related to Substance Use Disorders
DSM-IV and DSM 5 Diagnostic Codes Related to Substance Use Disorders (*Note: DSM 5 was released in May 2013 and includes significant changes to diagnosis. For example, it does away with separate "dependence" and "abuse" diagnoses and combines them into "substance use disorder.")
- DSM 5 Substance-Related and Addictive Disorders
The APA's breakdown on changes to substance-related addictive disorder diagnoses introduced by DSM-5. The document goes over substance use disorder, addictive disorders and briefly states the APA's position on caffeine use disorder.
- DSM SCID
The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) is a semi-structured interview for making the major DSM-IV Axis I diagnoses. The SCID-II is a semi-structured interview for making DSM-IV Axis II: Personality Disorder diagnoses. In addition to the important distinction between the SCID-I and SCID-II, there are several different versions and editions of the SCID.
- Electronic Prescriptions for Controlled Substances (EPCS) General Questions and Answers
The questions and answers are intended to summarize and provide general information regarding the Drug Enforcement Administration (DEA) Interim Final Rule with Request for Comment "Electronic Prescriptions for Controlled Substances" (21 CFR Parts 1300, 1304, 1306 and 1311; October 19, 2011) [Docket No. DEA-360].
- Example of Office-Based Opioid Treatment Policies
- FDA Approves 7-Day Buprenorphine Pain Patch (available upon free sign in)
This medical news article talks about the FDA approval of Butrans and provides a summary of clinical study findings, drug administration, and warnings and adverse events.
- FDA Drug Safety Information for Providers and Patients: Buprenorphine tablets
Buprenorphine tablets are approved for the treatment of opiate dependence. Buprenorphine treats opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.
- FDA Pregnancy Categories
Description of the FDA Pregnancy Categories with example drugs or substances.
- Flowchart of Steps in Applying for DEA Registration
Steps in Applying for DEA Registration
- Formulary Finder for Prescription Drug Plans
This is a database that allows users to search Medicare Prescription Coverage and Medicare Advantage Prescription Drug Plans by State.
- Free Drug Card Program
The Free Drug Card Program was developed to help uninsured and under insured Americans afford their prescription needs. It offers a free Prescription Drug Card that can be taken to a pharmacy to lower prescription drug costs.
- Frequently Asked Questions Applying the Substance Abuse Confidentiality Regulations to Health Information Exchange (HIE)
An educational document from the Substance Abuse and Mental Health Services Administration (SAMHSA) and the U.S. Department of Health and Human Services on the frequently asked questions in regard to substance abuse confidentiality regulations
- FSMB Model Policy for the Use of Controlled Substances for the Treatment of Pain
This document, first published in 2004 and revised in July 2013, is a model policy for state medical boards to use in developing their guidelines for use of opioids in treating chronic pain. These Model Guidelines provide the FSMB's policy on proper treatment of pain and the use of opioids when necessary to manage pain.
Federal State Medical Boards (FSMB)
- Hablando con su médico (Talking to Your Doctor (en Español))
This patient handout sheet discusses the importance of honesty from both the patient and the doctor when talking about drug use and treatment.
- Healthcare Access in Rural Communities
This website offers information about rural health programs and providing access to treatment, as well as Medicare and Medicaid funding for certain services and treatments in order to increase patient access to health care.
- Helping Smokers Quit A Guide for Clinicians
A website that explains the 5 A's for tobacco cessation.
- Hepatitis in Opioid Addiction Treatment
This publication discusses the medical co-management of hepatitis infection and opioid abuse.
- Home Buprenorphine / Naloxone Induction in Primary Care
This abstract discusses a study done on the feasibility of an unobserved buprenorphine induction protocol. The study involved 103 patients who were heroin users and prescription opioid misusers, and discusses safety and rates of complications from induction through follow-up.
- Información sobre la Buprenorfina (The Facts about Buprenorphine for Treatment of Opioid Addiction (en Español))
Ofrece información a los pacientes sobre la buprenorfina y los tratamientos con ayuda de medicamentos para tratar la adicción a los opioides, y también decribe la adicción y los síntomas del síndrome de abstinencia. Además, explica cómo funciona la buprenorfina, su uso apropiado, sus efectos secundarios y cómo se la utiliza en conjunto con la consejería en el proceso de recuperación.
- Links to State Health Department Websites
List of contact information and websites for all of the state health departments.
- Management Guidelines - Patient Maintained on Buprenorphine Scheduled for Surgery or other Procedures
Guidelines from Boston Medical Center designed for patient maintained on buprenorphine underdoing invasive procedures.
- Medical Recordkeeping
A description of what should be included in a buprenorphine patient's medical record.
- Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements
Describes reporting rule for those approved to prescribe buprenorphine to up to 275 patients.
- Medication Guide: Butrans™ CIII (buprenorphine) Transdermal System
This Medication Guide provides basic information about Butrans, the prescription medicine used for the management of moderate to severe chronic pain in patients requiring an around-the-clock opioid analgesic for a long period of time.
- Medication Guide: Suboxone Sublingual Film (CIII)
Patient information sheet on buprenorphine plus naloxone sublingual film
- Michigan Alcohol Screening Test (MAST), Revised
Drinking too much? Test yourself and your own use or abuse of alcohol with this 22-question quiz. Focusing specifically on alcohol use, this self-test does not address the use of other drugs.
- Models of Buprenorphine Induction
A learning activity that includes the different clinical models of buprenorphine induction, the associated evidence, and the pros and cons of each.
- Monitoring of liver function tests and hepatitis in patients receiving buprenorphine/ naloxone
This web page provides brief recommendations for monitoring patients undergoing buprenorphine treatment using liver function tests, and the proper actions to take if a patient develops hepatitis.
- Motivational Interviewing Overview
This web page is dedicated to motivational interviewing training. It contains links to a variety of articles, addressing all areas of MI from brief overviews to history, philosophy, principles, working with resistance, interaction techniques, and strategies. The site has a library, training information, and special populations information.
- NAABT Coding Grid
Displays the appropriate CPT and HCPCS billing codes for the different phases of buprenorphine treatment.
- Narcotics Anonymous: Find A Meeting
This page provides a search form for regional branches of Narcotics Anonymous to locate meetings in a specific area.
- National Institute on Drug Abuse Research Report on HIV/AIDS
This report by NIDA discusses the HIV/AIDS epidemic and how treating drug abuse is effective in preventing HIV.
The Needymeds website provides information on the Suboxone assistance program, a program that offers free suboxone medication to low-income patients who meet all eligibility requirements. It also includes important contact information, suboxone doses that are part of the program, the roles of the physician and patient in the application process, and application requirements.
- Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure (NEJM article; Dec 2010)
Presently, methadone is the recommended treatment for opioid-dependent pregnant women, but is associated with neonatal abstinence syndrome (NAS). NAS is characterized by opioid withdrawal symptoms in the newborn, which often requires longer hospitalization and treatment. Buprenorphine, FDA-approved in 2002 for the treatment of opioid dependence in non-pregnant individuals, hasn't been extensively studied during pregnancy. Yet, a new study in the New England Journal of Medicine (NEJM) found that buprenorphine offers an alternative to methadone in the treatment of opioid-dependent pregnant women. The study compared buprenorphine to methadone in 131 mothers and their newborns at eight international sites.
- NIDA Quick Screen
The NIDA Quick Screen can be used in clinical practice to screen patients for substance use disorders.
- NM ASSIST
The NM ASSIST is a screening tool that can be used in primary care to detect drug and alcohol abuse. The full version of the tool includes step-by-step screening algorithms.
- Nurse Practitioners and Physician Assistants Prescribing Buprenorphine
Describes and interprets the impact of Section 303 of the Comprehensive Addiction and Recovery Act (CARA), signed into law by President Obama on July 22, 2016. One of the changes allows nurse practitioners and physician assistants to prescribe buprenorphine with the appropriate training.
- Nursing Follow-up Visit
This form can be used by nurses to note the areas that should be covered during a follow-up visit for patients on buprenorphine treatment.
- Nursing Intake Screener
This form provides a list and a place to document important information that should be recorded during the intake assessment, including whether the patient is pregnant, taking other drugs, on methadone or has other addiction behaviors.
- Objective Opiate Withdrawal Scale (OOWS)
The Objective Opiate Withdrawal Scale (OOWS) contains 13 physically observable signs, rated present or absent, based on a timed period of observation of the patient by a rater.
- Office-Based Treatment: Training Your Staff
Your staff will be assisting you with many of the tasks essential to conducting in-office buprenorphine treatment. Therefore, staff members need a firm grasp of the principles of addiction treatment and corresponding clinical skills and an attitude conducive to working with this patient population. The staff's attitudes will affect the way they treat patients, thus influencing the outcome of treatment. Before starting office-based buprenorphine treatment, you may wish to conduct formal training with your staff. The brief guidelines below can help you structure your training.
- Opioid Overdose Prevention Toolkit
Includes several resources: Facts for Community Members; Essentials for First Responders; Safety Advice for Patients; Information for Prescribers; and Resources for Overdose Survivors and Family Members
- Opioid Treatment Program Directory
Find Opioid Treatment Programs by state.
- Opioid Use Disorder Diagnostic Criteria
The Diagnostic criteria for opioid use disorder,
- Patient Assessment Checklist
Before starting office-based buprenorphine treatment, the following Patient Assessment Questions should be answered for each patient. Topics addressed in these questions include: Diagnosis, Medications, Drugs/Alcohol, Psychiatric and Medical Comorbidities, Psychosocial Issues, Treatment, Patient Management, and Resources.
- Patient Handout: The Facts about Buprenorphine for Treatment of Opioid Addiction
This patient booklet is free to download from the Substance Abuse and Mental Health Services Administration (SAMHSA). It gives patients information on buprenorphine and medication-assisted treatment for opioid addiction. Describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.
- Patient Rights: Confidentiality and Consent
This is a patient handout to inform patients about their rights when undergoing office-based buprenorphine treatment.
- Patient Satisfaction Survey
Provides a downloadable patient satisfaction form. The survey assesses satisfaction with the health center and staff.
- PCCS-MAT Mentoring Program
PCSS-MAT provides ongoing mentoring programs aimed at improving providers confidence in treating opioid use disorder. The PCSS-MAT program is designed to assist providers in incorporating the use of medications for prescription opioid addicted patients in their practices. The mentoring program is available, at no cost to providers. PCSS-MAT mentors are a national network of trained providers with expertise in medication-assisted treatment and skilled in clinical education. Mentors provide support by telephone, email, or in person if logistically possible.
- PCSS-MAT Guidance: Clinically Relevant Drug Interactions of Buprenorphine or Methadone with Other Frequently Prescribed Drugs
Guideline document discussing interactions between buprenorphine and HIV medication.
- PCSS-MAT Guidance: Drug Enforcement Administration Requirements for Prescribers and Dispensers of Buprenorphine and Buprenorphine Naloxone
This clinical guidance provides information about the requirements for storing, dispensing, and maintaining records for physicians who provide office-based opioid treatment.
- PCSS-MAT Guidance: Management of Psychiatric Medications in Patients Receiving Buprenorphine/ Naloxone
This document describes how to manage medications for co-occuring psychiatric disorders in a patient receiving buprenorphine.
- PCSS-MAT Guidance: Pregnancy and Buprenorphine Treatment
Four-page document discussing treatment of pregnant patients with buprenorphine.
- PCSS-MAT Guidance: Transfer from Methadone to Buprenorphine
Document written to assist physicians in deciding which patients receiving methadone are good candidates for transfer to buprenorphine, and how to go about making this transition.
- PCSS-MAT Guidance: Treatment of Acute Pain in Patients Receiving Buprenorphine / Naloxone
This article provides guidance on the management and treatment of acute pain in patients receiving buprenorphine/naloxone.
- PCSS-MAT Guidance: Treatment of Opioid Dependent Adolescents and Young Adults Using Sublingual Buprenorphine
This document discusses the evidence for buprenorphine treatment of opioid dependent adolescents and young adults. It provides treatment recommendations, and highlights special issues that should be considered when treating this special population.
- PEG: A Three-Item Scale Assessing Pain Intensity and Interference
- Pharmacy Consent Form for Buprenorphine Treatment
By signing this Appointed Pharmacy Consent Form, the patient authorizes a provider to disclose to the pharmacy that he or she is being treated for opioid dependence; the pharmacy is also authorized to contact the provider to discuss treatment.
- Physician Clinical Support System - Buprenorphine (PCSS-MAT)
This website is designed to support physicians who prescribe buprenorphine by linking them up with a national network of trained physician mentors.
- Prescription Drug Monitoring Program Training and Technical Assistance Center
PDMO TTAC at Brandeis University provides support and resources for multiple stakeholders regarding PDMPs/
- Principles of Drug Addiction Treatment, A Research-Based Guide
This booklet provides a general overview of the principles that characterize effective treatment for drug addiction, and can be used to introduce staff and patients to this topic.
- Protracted Withdrawal
Bulletin describes the phenomenon of protracted withdrawal from addictive substances, including opioids, lasting months to years.
- Provider's Clinical Support System MAT
Provider's Clinical Support System (PCSS-MAT) is a national training and mentoring project. Offerings include online training modules and webinars, resources, and a mentor program for providers of medication assisted treatment who are getting started or have less experience.
- Psychosocial Aspects of Treatment in Patients Receiving Buprenorphine / Naloxone
Discussing the psychosocial aspects of treatment in patients receiving Buprenorphine/Naloxone
- Referral and consultation communication between primary care and specialist physicians: finding common ground
This study found that specialists and PCPs perceive the quality of their communications with each other differently regarding referral and consultations. Physicians who did not receive timely communications regarding referrals or consultation reported that it impacted their ability to provide high quality care. This highlights the importance of effective referral as a clinical skill, and the need to improve inter-profession communication between primary care physicians and specialists.
- Risk and Protective Factors in Drug Abuse Prevention
This is a brief list of risk and protective factors to look for when evaluating patients for substance abuse.
- Risk Factors: How can health professionals mitigate these risks?
This is a brief list of risk factors to look for when evaluating patients for substance abuse. There is also guidance on how health professionals can mitigate adolescent risk for substance abuse.
- SAMHSA's Buprenorphine Physician and Treatment Program Locator
A directory of treatment programs and physicians authorized to treat patients with buprenorphine.
- SAMHSA/CSAT Evaluation of the Buprenorphine Waiver Program
This report, written in 2006, evaluates patient outcomes and patient and provider attitudes since the passage of DATA 2000, and examines challenges facing buprenorphine treatment going forward.
- SAMHSA Buprenorphine Clinical Discussion WebBoard for Waived Physicians
The SAMHSA waived physician webboard is a moderated password-protected website in which physicians holding waivers from SAMHSA under the authority of the Drug Addiction Treatment Act of 2000 (DATA 2000) can ask and answer clinical questions about buprenorphine and opioid addiction. Physicians must register and login to access the WebBoard.
- SAMHSA Medication Assisted Treatment Website
Created by SAMHSA, this website section provides information about buprenorphine, including resources, the waivering process, DATA 2000, and the latest news.
- SAMHSA Provider Waiver Qualifications
Information from the CSAT Buprenorphine Information Center on the criteria required to receive waiver under DATA 2000.
- SAMHSA Section II: Guidelines (Medical Records)
These guidelines include a "Medical Record" section of what should be included in a buprenorphine patient's medical record.
- SAMHSA TIP 43, Chapter 9: Drug Testing as a Tool
This chapter from TIP 43: Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs discusses the use of drug testing as a means of monitoring patient progress and treatment efficacy. This chapter details several methods for implementing drug testing, their effectiveness, and their pros and cons.
- Sample Consent Form
This is a sample of a consent form that can be used when initiating buprenorphine treatment for a new patient.
- Sample Treatment Agreement/Contract (TIP 40 Appendix H)
Patient contract that can be used to set expectations and guidelines before beginning buprenorphine treatment.
- Schedule of Opioids
A table showing the schedule of opioids.
- Self-Administered Addiction Severity Index (ASI-Self Report)
The ASI Self-Report Form asks questions about the following topics: your background and employment, your health and family relationships, your legal situation, and your drug and alcohol use.
- Side Effect Management
This form provides a list of possible symptoms that a patient may have during buprenorphine treatment, possible causes, and recommended management of the symptoms.
- Side Effect Management
A table describing the management of side effects.
- Signs and Symptoms of Opioid Intoxication and Withdrawal
A description of the signs of opiate withdrawal useful for physicians in determining withdrawal during medically supervised detoxification.
- Sleep Hygiene Tips
List of sleep hygiene tips that can be used to improve sleep
- Stages of Change Model
The Stages of Change Model can be used to assess the patient's readiness to change his/her addictive behavior; this should be determined before addiction treatment begins.
- Subjective Opiate Withdrawal Scale (SOWS)
The Subjective Opiate Withdrawal Scale (SOWS) contains 16 symptoms whose intensity the patient rates on a scale of 0 (not at all) to 4 (extremely).
- Suboxone Prescribing Information
This provides prescribing information for Suboxone sublingual film and includes information on indications, dosing, contraindications, adverse reactions, drug interactions and use in specific populations.
- Suboxone Prescription Guide
Medication guide for Suboxone
- Substance Abuse Treatment for Persons With Co-Occurring Disorders Treatment Improvement Protocol (TIP) Series, No. 42
This TIP, Substance Abuse Treatment for Persons With Co-Occurring Disorders, revises TIP 9, Assessment and Treatment of Patients With Coexisting Mental Illness and Alcohol and Other Drug Abuse. The revised TIP provides information about new developments in the rapidly growing field of co-occurring substance use and mental disorders and captures the state-of-the-art in the treatment of people with co-occurring disorders. The TIP focuses on what the substance abuse treatment clinician needs to know and provides that information in an accessible manner. The TIP synthesizes knowledge and grounds it in the practical realities of clinical cases and real situations so the reader will come away with increased knowledge, encouragement, and resourcefulness in working with clients with co-occurring disorders.
- Substance Use Disorder Treatment for Adults and Adolescents
Describes the National Commission on Correctional Health Care position for how to treat substance use disorders for people in custody. It focuses on alcohol, benzodiazepine, and opioid use disorders.
- Talking to Your Provider
This patient handout sheet discusses the importance of honesty from both the patient and the provider when talking about drug use and treatment.
- TAP 28: The National Rural Alcohol and Drug Abuse Network Awards for Excellence 2004
This publication showcases seven papers written on issues relevant to rural substance abuse treatment and contains a list of resources on rural substance abuse issues.
- TAP 32: Clinical Drug Testing in Primary Care
- The ASAM Criteria
Described on the ASAM website as, "the most widely used and comprehensive set of guidelines for placement, continued stay and transfer/discharge of patients with addiction and co-occurring conditions.
- The ASAM National Practice Guideline (Medication Assisted Treatment)
This document outlines the 2015 guidelines for assessment and pharmacological treatment of patients with opioid use disorder.
- The Confidentiality of Alcohol and Drug Abuse Patient Records Regulation and the HIPAA Privacy Rule
Comprehensive document detailing the HIPAA Privacy Rule and its implications for alcohol and substance abuse programs.
- The National Alliance of Advocates for Buprenorphine Treatment (NAABT)
This website is for both buprenorphine patients and providers. It provides education on opioid addiction and buprenorphine treatment, and also connects patients in need of treatment to qualified treatment providers.
- The Rural Assistance Center Substance Abuse Information Guide
RAC helps rural communities and other rural stakeholders access the full range of available programs, funding, and research that can enable them to provide quality health and
human services to rural residents.
The Two-Item Conjoint Screening (TICS) scale is a brief screening tool. It screens for current substance use or dependence in a primary care population.
- TIP 26: Substance Abuse Among Older Adults
Guideline document designed to aid treatment providers deliver better services to elderly patients with substance use disorders.
- TIP 32: Treatment of Adolescents with Substance Use Disorders
The TIP 32 aims to help treatment providers design and deliver better services to adolescent clients with substance use disorders.
- TIP 35: Enhancing Motivation for Change in Substance Abuse Treatment
Guide on using motivation to effect substance abuse treatment. Includes information on motivational interviewing, integrating motivational approaches into treatment, and measuring patient motivation.
- TIP 43. Chapter 10: Associated Medical Problems in Patients Who Are Opioid Addicted
This chapter of TIP 43 is aimed to help treatment providers identify co-occurring medical problems in patients who are addicted to opioids.
- TIP 54: Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders
Practical tools and guidance for treating chronic pain in adults who have a history of substance use disorders. Topics include chronic pain management, treatment with opioids, substance abuse assessments and referrals.
- Tobacco Use Assessment Form
Tobacco Use Assessment Form
- Transfer from Methadone Form
This form provides a list of important considerations when determining whether a methadone patient is a candidate for transfer to buprenorphine treatment, including social, medical, and psychiatric history.
- Using Motivational Interviewing in Routine Care
A presentation by Bruce J. Rounsaville about motivational interviewing in the primary care setting.
- VA/DoD Clinical Practice Guideline for the Management of Opioid Therapy for Chronic Pain
The guideline provides recommendations for practice interventions and evaluations when using opioid therapy to treat chronic non-cancer pain. It is entirely evidence-based and uses clinical algorithms to optimize the use of opioid therapy.
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders
2015 version. 169 pages.
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders Stabilization Pocket Card
A reference tool used to provide clinicians with stabilization resources for substance use disorder within active duty and veteran populations, including resources on pharmacological treatment and substance titration.
- VIDEO: Patient Mike's Story
View three short webisodes that share Mike's buprenorphine success story. This story was taken from The National Alliance of Advocates for Buprenorphine Treatment (NAABT.org). Mike is an average middle-class American, a business owner, and a loving husband, father, and grandfather. While remodeling his restaurant, he hurt himself, and slowly became addicted to prescription opioid painkillers. A medication called buprenorphine, in addition to counseling and support, would allow him to get back on a productive path.
- Withdrawal Versus Precipitated Withdrawal
Two types of withdrawal are associated with mu opioid agonist dependence: withdrawal and precipitated withdrawal.
- XR-Naltrexone: A Step-by-Step Guide
This step-by-step guide provides medical professionals a clear clinical plan from patient history intake to follow-up visit after administering XR-Naltrexone injections.